Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.70 |
| ▸ | MAPT | P10636 | 3/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.54 |
| ▸ | CRHBP | P24387 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | PPARD | Q03181 | 10/20 | 0.47 |
| ▸ | PPARA | Q07869 | 9/20 | 0.47 |
| ▸ | PPARG | P37231 | 5/20 | 0.47 |
| ▸ | FFAR1 | O14842 | 6/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16399681 | 0.86 | L3MBTL1 (0.68) | L3MBTL1MAPTMEN1KMT2ANPC1 | |
| SCHEMBL18003089 | 0.86 | L3MBTL1 (0.76) | L3MBTL1MAPTKDM4EMEN1KMT2A | |
| SCHEMBL16399060 | 0.84 | L3MBTL1 (0.62) | L3MBTL1MAPTKDM4EMEN1HSP90AA1 | |
| SCHEMBL18003085 | 0.84 | L3MBTL1 (0.78) | L3MBTL1MAPTKDM4EMEN1KMT2A | |
| SCHEMBL16399399 | 0.83 | L3MBTL1 (0.55) | L3MBTL1MAPTKDM4EMEN1HSP90AA1 | |
| SCHEMBL18003913 | 0.83 | L3MBTL1 (0.58) | L3MBTL1MAPTKDM4EMEN1HSP90AA1 | |
| SCHEMBL18003992 | 0.83 | MAPT (0.54) | L3MBTL1MAPTKDM4EMEN1HSP90AA1 | |
| SCHEMBL18003676 | 0.83 | L3MBTL1 (0.76) | L3MBTL1MAPTKDM4EKMT2ANPC1 | |
| SCHEMBL18003464 | 0.82 | L3MBTL1 (0.60) | L3MBTL1MAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL2946732 | 0.82 | L3MBTL1 (0.78) | L3MBTL1MAPTKDM4EMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4219477-A1 | CYANOTRIAZOLE COMPOUNDS | Otsuka Pharmaceutical Co., Ltd. (JP) | 2023-08-02 | — | — | EP | disclosed |
| US-10626095-B2 | Cyanotriazole compounds | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2020-04-21 | — | — | US | disclosed |
| US-20160229816-A1 | CYANOTRIAZOLE COMPOUNDS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2016-08-11 | — | — | US | disclosed |
| US-20160229816-A1 | CYANOTRIAZOLE COMPOUNDS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2016-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10626095-B2 | Cyanotriazole compounds | CS, PC, ACAT1 | L3MBTL1 1503/4885MAPT 2196/4885KDM4E 2681/4885 |
| US-20160229816-A1 | CYANOTRIAZOLE COMPOUNDS | CS, PC, ACAT1 | L3MBTL1 1503/4885MAPT 2196/4885KDM4E 2681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.